Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of apremilast in pediatric moderate to severe plaque psoriasis
2019-003497-13Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apremilast in plaque psoriasis, sponsored by Celgene Corporation. Primary endpoint: Adverse events. Started Feb 2020; status: active.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2019-003497-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003497-13.